Victory Capital Management Inc. increased its stake in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 44.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 59,211 shares of the biotechnology company’s stock after purchasing an additional 18,190 shares during the period. Victory Capital Management Inc. owned approximately 0.22% of Aclaris Therapeutics worth $1,528,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Rosenblum Silverman Sutton S F Inc. CA increased its position in shares of Aclaris Therapeutics by 8.3% in the third quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 41,600 shares of the biotechnology company’s stock worth $1,074,000 after purchasing an additional 3,200 shares during the period. Ardsley Advisory Partners acquired a new stake in Aclaris Therapeutics in the second quarter valued at about $407,000. California State Teachers Retirement System boosted its stake in Aclaris Therapeutics by 60.8% in the second quarter. California State Teachers Retirement System now owns 35,696 shares of the biotechnology company’s stock valued at $968,000 after buying an additional 13,500 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in Aclaris Therapeutics by 69.7% in the second quarter. The Manufacturers Life Insurance Company now owns 15,831 shares of the biotechnology company’s stock valued at $429,000 after buying an additional 6,502 shares in the last quarter. Finally, Redmile Group LLC boosted its stake in Aclaris Therapeutics by 4.3% in the second quarter. Redmile Group LLC now owns 94,560 shares of the biotechnology company’s stock valued at $2,564,000 after buying an additional 3,860 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.
Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) traded up $0.09 during mid-day trading on Thursday, hitting $22.11. The stock had a trading volume of 284,341 shares, compared to its average volume of 279,861. Aclaris Therapeutics Inc has a 12-month low of $21.32 and a 12-month high of $33.25.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.23. The firm had revenue of $0.68 million for the quarter, compared to analyst estimates of $2.00 million. sell-side analysts anticipate that Aclaris Therapeutics Inc will post -2.59 EPS for the current fiscal year.
Several analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Aclaris Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research lowered Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. ValuEngine lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. JMP Securities reaffirmed an “outperform” rating and issued a $39.00 price objective on shares of Aclaris Therapeutics in a research note on Friday, September 8th. Finally, BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 16th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Aclaris Therapeutics currently has an average rating of “Hold” and an average price target of $39.20.
ILLEGAL ACTIVITY NOTICE: “Aclaris Therapeutics Inc (NASDAQ:ACRS) Position Boosted by Victory Capital Management Inc.” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/07/aclaris-therapeutics-inc-acrs-position-increased-by-victory-capital-management-inc.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.